Grapefruit Juice Interactions

58 interactions on record

Inhibits CYP3A4 activity, increasing systemic budesonide exposure. Avoid ingestion with budesonide.

Source: NLP:budesonide

Strong CYP3A4 inhibitor that increases elinzanetant exposure, raising risk of adverse reactions. Avoid concomitant use.

Source: NLP:elinzanetant

CYP3A4 inhibitor increases risk of myopathy by reducing lovastatin elimination.

Source: NLP:lovastatin

Strong CYP 3A4 inhibitor; rare reports of serious adverse events with ergot alkaloids including vasospasm leading to cerebral ischemia and/or extremity ischemia.

Source: NLP:methylergonovine maleate

CYP3A4 inhibitor; simultaneous use with both CYP2D6 and CYP3A4 inhibitors should be avoided due to increased risk of proarrhythmia.

Source: NLP:propafenone hydrochloride

Grapefruit juice inhibits CYP3A4-mediated metabolism of sirolimus and must not be taken with or used for dilution of sirolimus.

Source: NLP:sirolimus

Strong CYP3A inhibitor that may increase tacrolimus concentrations and risk of serious adverse reactions including neurotoxicity and QT prolongation.

Source: NLP:tacrolimus

Moderate CYP3A4 inhibitor increases cilostazol exposure. Requires cilostazol dose reduction to 50 mg twice daily.

Source: NLP:cilostazol

Toxicities reported when colchicine is administered with grapefruit juice, a CYP3A4 inhibitor. Serious and life-threatening toxicity potential.

Source: NLP:colchicine

Moderate or strong CYP3A4 inhibitor; reduce EMFLAZA dose to one third of recommended dosage when used concomitantly.

Source: NLP:deflazacort

Strong CYP3A4 inhibitor increases erlotinib exposure, raising risk of exposure-related toxicity. Avoid co-administration or reduce erlotinib dosage if unavoidable.

Source: NLP:erlotinib

CYP3A4 inhibitor resulting in more than 2-fold increase in AUC and Cmax of felodipine without prolongation in half-life.

Source: NLP:felodipine

CYP3A4 inhibitor that increases fentanyl plasma concentration, resulting in increased or prolonged opioid effects, respiratory depression, and sedation.

Source: NLP:fentanyl

CYP3A4 inhibitor that increases fentanyl plasma concentration, resulting in increased or prolonged opioid effects and respiratory depression.

Source: NLP:fentanyl citrate

CYP3A4 inhibitor; concomitant use can increase plasma concentration of fentanyl, resulting in increased or prolonged opioid effects, respiratory depression, and sedation.

Source: NLP:fentanyl transdermal

Avoid grapefruit juice due to increased simvastatin plasma levels and risk of myopathy and rhabdomyolysis.

Source: NLP:simvastatin

CYP3A inhibitor that increases tolvaptan exposure. Patients should avoid grapefruit juice beverages.

Source: NLP:tolvaptan

Possible drug interaction with alprazolam based on clinical studies in other benzodiazepines. Caution recommended.

Source: NLP:alprazolam

Grapefruit juice may increase exposure of cabozantinib, increasing risk of exposure-related adverse reactions. Avoid coadministration or reduce CABOMETYX dosage.

Source: NLP:cabozantinib

CYP3A4 inhibitor that increases carbamazepine plasma levels. Close monitoring of carbamazepine levels and dosage adjustment may be required.

Source: NLP:carbamazepine

CYP3A4 inhibitor may increase dronabinol systemic exposure and adverse reactions; monitor for increased dronabinol-related effects.

Source: NLP:dronabinol

Strong CYP3A4 inhibitor that increases encorafenib plasma concentrations and may increase adverse reactions. Avoid coadministration; if unavoidable, reduce encorafenib dose.

Source: NLP:encorafenib

CYP3A4 inhibitor that may increase plasma concentrations of estradiol and may result in side effects.

Source: NLP:estradiol

CYP3A4 inhibitor may increase serum hydrocortisone concentrations and risk of adverse reactions; may require dose decrease.

Source: NLP:hydrocortisone

Grapefruit juice may increase plasma concentrations of imatinib; avoid concomitant use.

Source: NLP:imatinib

Moderate CYP3A4 inhibitor that increases ivabradine plasma concentrations. Avoid concomitant use.

Source: NLP:ivabradine

Inhibits CYP3A4 and increases nimodipine plasma concentration. Ingestion of grapefruit/grapefruit juice is not recommended while taking nimodipine.

Source: NLP:nimodipine

Strong CYP3A inhibitor that increases paricalcitol exposure. Dose adjustment may be necessary; monitor iPTH and serum calcium.

Source: NLP:paricalcitol

CYP3A inhibitor that increases ranolazine exposure. Limit ranolazine to 500 mg twice daily.

Source: NLP:ranolazine

Moderate CYP3A inhibitor; recommended suvorexant dose is 5 mg, may increase to 10 mg if needed.

Source: NLP:suvorexant

Coadministration increased maximum plasma concentration by 25%, area under curve by 48%, and half-life by 18%.

Source: NLP:triazolam

May significantly increase verapamil concentrations (AUC increased 28-36%, Cmax increased 40-57%), though clinical consequences not expected.

Source: NLP:verapamil hydrochloride

CYP3A inhibitor not expected to have significant effect on prasugrel active metabolite pharmacokinetics.

Source: NLP:prasugrel